Christopher Bowden
2016
In 2016, Christopher Bowden earned a total compensation of $1.8M as Chief Medical Officer at Agios Pharmaceuticals, a 23% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $174,440 |
|---|---|
| Option Awards | $1,145,987 |
| Salary | $436,091 |
| Other | $9,103 |
| Total | $1,765,621 |
Bowden received $1.1M in option awards, accounting for 65% of the total pay in 2016.
Bowden also received $174.4K in non-equity incentive plan, $436.1K in salary and $9.1K in other compensation.
Rankings
In 2016, Christopher Bowden's compensation ranked 5,467th out of 14,075 executives tracked by ExecPay. In other words, Bowden earned more than 61.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,467 out of 14,075 | 61st |
Division Manufacturing | 1,959 out of 5,488 | 64th |
Major group Chemicals And Allied Products | 620 out of 1,900 | 67th |
Industry group Drugs | 463 out of 1,543 | 70th |
Industry Pharmaceutical Preparations | 368 out of 1,173 | 69th |
Source: SEC filing on April 18, 2018.
Bowden's colleagues
We found five more compensation records of executives who worked with Christopher Bowden at Agios Pharmaceuticals in 2016.
2016
Andrew Hirsch
Agios Pharmaceuticals
Chief Financial Officer
2016
Steve Hoerter
Agios Pharmaceuticals
Chief Commercial Officer
2016
David Schenkein
Agios Pharmaceuticals
Chief Executive Officer
2016
Scott Biller
Agios Pharmaceuticals
Chief Scientific Officer
2016
Glenn Goddard
Agios Pharmaceuticals
Former Sr. Vice President, Finance
News
Agios Pharmaceuticals CEO Jacqualyn Fouse's 2021 pay slips 14% to $6.5M
April 28, 2022
Agios Pharmaceuticals CEO Jacqualyn Fouse's 2020 pay falls 54% to $7.6M
April 8, 2021
Agios Pharmaceuticals CEO Jacqualyn Fouse receives $17M in 2019
April 16, 2020
Agios Pharmaceuticals CEO David Schenkein's 2018 pay jumps 37% to $8.2M
April 18, 2019